613 related articles for article (PubMed ID: 30096846)
1. Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.
Marín MQ; Pérez P; Gómez CE; Sorzano CÓS; Esteban M; García-Arriaza J
Viruses; 2018 Aug; 10(8):. PubMed ID: 30096846
[TBL] [Abstract][Full Text] [Related]
2. Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.
García-Arriaza J; Arnáez P; Gómez CE; Sorzano CÓ; Esteban M
PLoS One; 2013; 8(6):e66894. PubMed ID: 23826170
[TBL] [Abstract][Full Text] [Related]
3. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
[TBL] [Abstract][Full Text] [Related]
4. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.
García-Arriaza J; Nájera JL; Gómez CE; Tewabe N; Sorzano CO; Calandra T; Roger T; Esteban M
PLoS One; 2011; 6(8):e24244. PubMed ID: 21909386
[TBL] [Abstract][Full Text] [Related]
5. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.
García-Arriaza J; Gómez CE; Sorzano CÓ; Esteban M
J Virol; 2014 Mar; 88(6):3392-410. PubMed ID: 24390336
[TBL] [Abstract][Full Text] [Related]
6. High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome.
Gómez CE; Perdiguero B; Cepeda MV; Mingorance L; García-Arriaza J; Vandermeeren A; Sorzano CÓ; Esteban M
J Virol; 2013 Jul; 87(13):7282-300. PubMed ID: 23596307
[TBL] [Abstract][Full Text] [Related]
7. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
[TBL] [Abstract][Full Text] [Related]
8. Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.
Tan WG; Zubkova I; Kachko A; Wells F; Adler H; Sutter G; Major ME
PLoS One; 2017; 12(7):e0181578. PubMed ID: 28732046
[TBL] [Abstract][Full Text] [Related]
9. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
[TBL] [Abstract][Full Text] [Related]
10. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
[TBL] [Abstract][Full Text] [Related]
11. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.
Swadling L; Capone S; Antrobus RD; Brown A; Richardson R; Newell EW; Halliday J; Kelly C; Bowen D; Fergusson J; Kurioka A; Ammendola V; Del Sorbo M; Grazioli F; Esposito ML; Siani L; Traboni C; Hill A; Colloca S; Davis M; Nicosia A; Cortese R; Folgori A; Klenerman P; Barnes E
Sci Transl Med; 2014 Nov; 6(261):261ra153. PubMed ID: 25378645
[TBL] [Abstract][Full Text] [Related]
12. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.
Ramírez JC; Gherardi MM; Esteban M
J Virol; 2000 Jan; 74(2):923-33. PubMed ID: 10623755
[TBL] [Abstract][Full Text] [Related]
13. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
14. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum.
Singh S; Vedi S; Li W; Samrat SK; Kumar R; Agrawal B
Vaccine; 2014 May; 32(23):2712-21. PubMed ID: 24631092
[TBL] [Abstract][Full Text] [Related]
15. Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.
Perdiguero B; Gómez CE; Nájera JL; Sorzano CO; Delaloye J; González-Sanz R; Jiménez V; Roger T; Calandra T; Pantaleo G; Esteban M
PLoS One; 2012; 7(10):e48524. PubMed ID: 23119046
[TBL] [Abstract][Full Text] [Related]
16. Characterizing the effects of insertion of a 5.2 kb region of a VACV genome, which contains known immune evasion genes, on MVA immunogenicity.
Ryerson MR; Shisler JL
Virus Res; 2018 Feb; 246():55-64. PubMed ID: 29341877
[TBL] [Abstract][Full Text] [Related]
17. T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates.
Rollier CS; Verschoor EJ; Verstrepen BE; Drexhage JA; Paranhos-Baccala G; Liljeström P; Sutter G; Arribillaga L; Lasarte JJ; Bartosch B; Cosset FL; Inchauspe G; Heeney JL
Gene Ther; 2016 Oct; 23(10):753-759. PubMed ID: 27416077
[TBL] [Abstract][Full Text] [Related]
18. Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-sensing pathway.
Dai P; Wang W; Cao H; Avogadri F; Dai L; Drexler I; Joyce JA; Li XD; Chen Z; Merghoub T; Shuman S; Deng L
PLoS Pathog; 2014 Apr; 10(4):e1003989. PubMed ID: 24743339
[TBL] [Abstract][Full Text] [Related]
19. Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene
Chea LS; Wyatt LS; Gangadhara S; Moss B; Amara RR
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541829
[TBL] [Abstract][Full Text] [Related]
20. Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice.
Guan J; Deng Y; Chen H; Yin X; Yang Y; Tan W
Arch Virol; 2015 Oct; 160(10):2517-24. PubMed ID: 26215441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]